

<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "journalpublishing3.dtd">
<article xmlns:xlink="https://www.w3.org/1999/xlink">
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">Avicenna J Med Biotech</journal-id>
      <journal-id journal-id-type="publisher-id">arij002</journal-id>
      <journal-title-group>
        <journal-title>Avicenna Journal of Medical Biotechnology</journal-title>
      </journal-title-group>
      <issn pub-type="ppub">2008-2835</issn>
      <issn pub-type="epub">2008-4625</issn>
      <publisher>
        <publisher-name>Avicenna Research Institute</publisher-name>
      </publisher>
    </journal-meta>

    <article-meta>
      <article-id pub-id-type="publisher-id">ajmb40475</article-id>
      <article-id pub-id-type="doi"></article-id>
      <article-id pub-id-type="pmid"></article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
             <subject></subject> 
        </subj-group>
        <subj-group>
            <subject></subject>
        </subj-group> 
      </article-categories>
      <title-group>
        <article-title>A Cross-Sectional Study for Evaluation of KRAS and BRAF Mutations by Reverse Dot Blot, PCR-RFLP, and Allele-Specific PCR Methods Among Patients with Colorectal Cancer</article-title>
      </title-group>
        <contrib-group><contrib contrib-type="author"><name><surname>Sheikhsofla</surname><given-names>Fatemeh</given-names></name></contrib></contrib-group><contrib-group><contrib contrib-type="author"><name><surname>Poopak</surname><given-names>Behzad</given-names></name></contrib></contrib-group><contrib-group><contrib contrib-type="author"><name><surname>Firuzyar</surname><given-names>Sajjad</given-names></name></contrib></contrib-group><contrib-group><contrib contrib-type="author"><name><surname>Roudbari </surname><given-names>Fatemeh</given-names></name></contrib></contrib-group><contrib-group><contrib contrib-type="author"><name><surname>Ghadiany</surname><given-names>Mojtaba</given-names></name></contrib></contrib-group>
      <pub-date pub-type="ppub">
        <day></day>
        <month></month>
        <year></year>
      </pub-date>
      <pub-date pub-type="epub">
        <day></day>
        <month></month>
        <year></year>
      </pub-date>
      <volume>13</volume>
      <issue>4</issue>
      <fpage>183</fpage>
      <lpage>191</lpage>
      <history>
        <date date-type="received">
          <day>9</day>
          <month>12</month>
          <year>2020</year>
        </date>
        <date date-type="accepted">
          <day>18</day>
          <month>4</month>
          <year>2021</year>
        </date>
      </history>
      <abstract>
      <p>
      &lt;p style=&quot;text-align:justify&quot;&gt;&lt;span style=&quot;font-size:11pt&quot;&gt;&lt;span style=&quot;font-size:9.5pt&quot;&gt;Background:&lt;/span&gt;&lt;span style=&quot;font-size:10.0pt&quot;&gt; &lt;em&gt;KRAS&lt;/em&gt; and &lt;em&gt;BRAF&lt;/em&gt; genes are the biomarkers in Colorectal Cancer (CRC) which play prognostic and predictive roles in CRC treatment. Nowadays, the selection of rapid and available methods for studying &lt;em&gt;KRAS&lt;/em&gt; and &lt;em&gt;BRAF&lt;/em&gt; mutations in anti-EGFR therapy of patients suffering from CRC plays a significant role. In this study, the mutations of these two oncogenes were evaluated by different methods.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style=&quot;text-align:justify&quot;&gt;&lt;span style=&quot;font-size:11pt&quot;&gt;&lt;span style=&quot;font-size:9.5pt&quot;&gt;Methods:&lt;/span&gt;&lt;span style=&quot;font-size:10.0pt&quot;&gt; This study was performed on 50 Formalin-Fixed Paraffin-Embedded (FFPE) tissue blocks of patients diagnosed with colorectal cancer. After DNA extraction, &lt;em&gt;KRAS&lt;/em&gt; and &lt;em&gt;BRAF&lt;/em&gt; gene mutations were evaluated using reverse dot blot, and results were compared with PCR-RFLP and allele-specific PCR for &lt;em&gt;KRAS&lt;/em&gt; and &lt;em&gt;BRAF&lt;/em&gt; mutations, respectively.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style=&quot;text-align:justify&quot;&gt;&lt;span style=&quot;font-size:11pt&quot;&gt;&lt;span style=&quot;font-size:9.5pt&quot;&gt;Results:&lt;/span&gt;&lt;em&gt;&lt;span style=&quot;font-size:10.0pt&quot;&gt; KRAS&lt;/span&gt;&lt;/em&gt;&lt;span style=&quot;font-size:10.0pt&quot;&gt; gene mutations were detected in 42% of patients, of which 30% were in codon 12 region, and 12% in codon 13. The most frequent mutations of &lt;em&gt;KRAS&lt;/em&gt; were related to G12D and 10% of patients had &lt;em&gt;BRAF&lt;/em&gt; mutated genes. &lt;/span&gt;&lt;span style=&quot;font-size:10.0pt&quot;&gt;The type of &lt;em&gt;KRAS&lt;/em&gt; gene mutations could be evaluated by reverse dot blot method. &lt;/span&gt;&lt;span style=&quot;font-size:10.0pt&quot;&gt;In&lt;/span&gt;&lt;span style=&quot;font-size:10.0pt&quot;&gt; general, the results of PCR-RFLP and allele-specific PCR were similar to the findings by reverse dot blot method.&amp;nbsp; &lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p&gt;&lt;span style=&quot;font-size:11pt&quot;&gt;&lt;span style=&quot;font-size:9.5pt&quot;&gt;Conclusion:&lt;/span&gt;&lt;span style=&quot;font-size:10.0pt&quot;&gt; These findings suggest that PCR-RFLP and allele-specific PCR methods are suitable for screening the presence of the mutations in &lt;em&gt;KRAS&lt;/em&gt; and &lt;em&gt;BRAF&lt;/em&gt; oncogenes. In fact, another method with more sensitivity is needed for a more accurate assessment to determine the type of mutations. Due to higher speed of detection, reduced Turnaround Time (TAT), and possible role of some &lt;em&gt;KRAS&lt;/em&gt; point mutations in overall survival, reverse dot blot analysis seems to be an optimal method.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

      </p>
      </abstract>
    </article-meta>
  </front>
    
</article>
